Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

J. Kim



Author of

  • +

    P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 210)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Localized Disease - NSCLC
    • Presentations: 1
    • +

      P2.02-039 - Patterns-Of-Care Study of Stereotactic Ablative Radiotherapy for Lung Cancer in Korea (ID 164)

      09:30 - 09:30  |  Author(s): J. Kim

      • Abstract

      Background:
      Stereotactic ablative radiotherapy (SABR) is an emerging effective technique for early stage lung cancer. We investigated the current practice patterns for stereotactic ablative radiotherapy (SABR) for lung cancer in Korea.

      Methods:
      A nationwide survey about experience with SABR for lung cancer was sent by e-mail to the radiation oncologists of 85 institutions in May 2014. SABR was defined as hypofractionated radiotherapy (1–8 fractions). The survey contained 23 questions, and those regarding technical details allowed multiple choices.

      Results:
      Of the 59 institutions that responded to the survey, 33 (56%) had used SABR for lung cancer. Thirty-seven radiation oncologists from these 33 institutions responded to the survey. Seventy-five percent of the oncologists had been treating lung cancer with SABR for less than 5 years, while 89% treat less than 20 cases annually. The most common planning method was rotational intensity-modulated technique (59%), followed by static intensity-modulated technique (49%). A wing board (54%) was most frequently used for immobilization, followed by the vacuum lock system (51%). Respiratory motion was managed by gating (54%) or abdominal compression (51%), and 86% of the planning scans were obtained with 4-dimensional computed tomography. More than half of the respondents (62%) treated daily if a multi-fraction regimen was used.

      Conclusion:
      The results of our survey indicated that SABR for lung cancer is being used increasingly in Korea, and that the majority of radiation oncologists using this therapy have limited experience in its use. There was wide variation among institutions with regard to the technical protocols, which indicates that standardization is necessary prior to the initiation of further nationwide multi-center, randomized studies.

  • +

    P3.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 214)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Locoregional Disease – NSCLC
    • Presentations: 1
    • +

      P3.03-031 - Predictors of Radiation Pneumonitis and Associated Changes of Pulmonary Function After Definitive Concurrent Chemoradiotherapy in NSCLC (ID 1490)

      09:30 - 09:30  |  Author(s): J. Kim

      • Abstract

      Background:
      To evaluate the predictive factors of radiation pneumonitis (RP) and associated changes of pulmonary function after definitive concurrent chemoradiotherapy (CCRT) in patients with NSCLC

      Methods:
      Medical records of 61 patients with NSCLC who received definitive CCRT at Seoul National University Bundang Hospital were retrospectively reviewed. Dose volumetric parameters, clinical factors, pulmonary function test (PFT) data were analyzed. RP was graded according to the Common Terminology Criteria for Adverse Events v3.0. Percentage of lung volume that received a dose of 10 Gy or more (V10), 20 Gy or more (V20), 30 Gy or more (V30), mean lung dose (MLD) were analyzed for potential dose volumetric (DV) parameters. PFT changes were calculated as the difference between pre-RT and post-RT values compared to the pre-RT values at 3, 6, 12 months after RT. Tumor location was categorized two groups, upper (including middle) and lower lobe.

      Results:
      The overall and progression-free survival time were 21.9 month and 10.6 months. Twenty-three patients (38%) developed grade≥2 RP. Among clinical factors, underlying chronic obstructive pulmonary disease was associated with RP (p=0.050) but not with grade ≥2 RP (p=0.871). Tumor located at lower lobe was associated with grade ≥2 RP (p=0.002). Among the DV parameters, only MLD > 15 Gy was associated with grade ≥2 RP (p=0.009). There were statistically significant decreases in PFT values at all points compared with pre-RT values. MLD was associated with magnitude of forced vital capacity (FVC) changes at 6/12 months (p=0.006/0.016) and forced expiratory volume in 1 s (FEV1) changes at 6 months (p=0.005). V10 and V20 were associated with FVC changes at 12 months (p=0.048/0.025) and V30 was associated with diffusion capacity for carbon monoxide changes at 6 months (p=0.023).

      Conclusion:
      MLD > 15 Gy and lower lobe tumor were predictors of grade ≥2 RP. Pulmonary functions were decreased after CCRT and the magnitude of change was associated with DV parameters.